INTRODUCTION
Of the recognized inherited disorders of porphyrin metabolism, the last to be described (3, 4) has been called "erythropoietic protoporphyria."1 The biochemical hallmark of this disorder is an increase in protoporphyrin concentration in red cells, stool, or both (6) . It is inherited as an autosomal dominant with variable penetrance and clinically is characterized by photosensitivity, which runs a benign course. However, several patients have developed cirrhosis and hepatic failure (7) (8) (9) (10) . The livers of these and some other, nonfatal cases have shown protoporphyrin pigment deposition in the biliary system, including the canaliculi, and in Kupffer cells and hepatocytes (11, 12) .
The nature and locus of the metabolic defect of heme biosynthesis have been unresolved questions in protoporphyria. A profound deficiency of erythropoietic heme synthesis does not usually occur, although patients may be anemic (7, 9, 10, 12) . Furthermore, hepatic heme biosynthesis appears to be normal although this is difficult to assess and has not been studied in detail.
Normally, the rate of heme biosynthesis is thought to be controlled primarily at the level of 8-aminolevulinic acid (ALA)' synthetase (succinyl-CoA-glycine succinyl transferase, EC 2.3.1.37), the first enzyme of the pathway, which is subject both to end-product (heme) repression and inhibition (6) . An increase in hepatic ALA synthetase activity occurs in the dominantly inherited hepatic porphyrias, acute intermittent porphyria (6, 13) , variegate porphyria in relapse (13) , and hereditary coproporphyria in relapse (14) . In the case of acute intermittent porphyria, this increase is believed to be secondary to a genetically determined deficiency of uroporphyrinogen I synthetase which may lead to partial heme deficiency and subsequent derepression and/or disinhibition of ALA synthetase until adequate amounts of end product are formed (15) (16) (17) (18) . Other factors outside the heme pathway affect the level of activity of ALA synthetase as well (6, (17) (18) (19) . A reasonable postulate is that the characteristic biochemical features of each of these diseases result from accumulation of different heme precursors behind an inherited partial enzyme deficiency unique to that disease, coupled with a secondary increase in ALA synthetase activity.
In protoporphyria, one might predict a partial deficiency of heme synthetase activity (protoheme ferrolyase, EC 4.99.1.1) to explain the observed findings. In an early in vitro study using liver and bone marrow from two brothers with protoporphyria, Porter failed to demonstrate a deficiency of incorporation of '9Fe into heme (20) . The significance of this is uncertain, however, since optimal conditions for assay (21, 22) were not employed. More recently two groups of workers independently have found evidence for decreased erythroid heme synthetase activity in three patients with protoporphyria (23, 24) .
In this study, we have measured heme synthetase activity in homogenates of liver and sonicates of cultured skin fibroblasts from controls and patients with protoporphyria. In addition ALA synthetase activity has been measured in lysates of the fibroblasts, both to serve as a mitochondrial "marker" and to provide further information regarding this enzyme in protoporphyria. 2Abbreviation used in this paper: ALA, 6-aminolevulinic acid.
METHODS Preparation of tissues
Fibroblasts. 4-mm punch biopsies of skin, from areas not chronically exposed to sunlight, were placed into tissue culture medium to establish fibroblast lines. Culture medium was Eagle's minimum essential medium with Earle's salts (Grand Island Biological Co., Grand Island, N. Y.) and 10% fetal calf serum (Flow Laboratories, Inc., Rockville, Md.) plus kanamycin (Grand Island Biological Co.), 100 ,ug/ml.
Fibroblasts were harvested at confluence from monolayer culture into Ca++-Mg++-free phosphate-buffered saline, pH 7.4, with 0.25% trypsin. They were centrifuged (1,000 g, 10 min, 4°C) and evenly resuspended in 5-7 ml 0.25 M sucrose-0.05 M Tris Cl (pH 7.5). Cell counts and estimates of viability (trypan blue exclusion) were performed on a suitable dilution of this suspension. Viability was 70-90%.
A portion of the cell suspension (15-20 X 106 cells) was centrifuged again and the cell button resuspended in 1-2 ml 0.154 M NaCl-0.04 M Tris Cl (pH 7.4) which was stored at -70°C until assay of ALA synthetase, 1-10 wk later. (Table II) were obtained as part of their evaluation and to aid in management. Liver was obtained from control 6 shortly after death and was stored and assayed simultaneously with the specimens from protoporphyria patients 9 and 10 to serve as a direct control for these patient specimens.
The biopsies were immediately placed into iced saline and divided. One part was placed into fixative for histologic study; the other was blotted, weighed, and frozen or homogenized fresh in 3.5 ml 0.25 M sucrose-0.05 M Tris Cl (pH 7.5) with a ground-glass semi-microhomogenizer (MicroMetric Corp., Cleveland, Ohio). Final Porphyrins. The dimethylesters of protoporphyrin (Sigma Chemical Co., St. Louis, Mo.), mesoporphyrin, and deuteroporphyrin (ICN K&K Laboratories, Inc., Plainview, N. Y.) were hydrolyzed by refluxing for 4-5 h 15 mg of the ester in 20 ml of a solution prepared by dissolving 1 g KOH in 96 ml methanol, 2 ml water, and 1 ml Tween-20. Undissolved ester was removed by filtration and the final concentration of free porphyrin determined by spectrophotometry on a 1/100 dilution of the filtrate in HCl (25) . The solutions were stored at -25°C, protected from light.
Hemnatin. 5 Heme synthetase. The conditions employed for assay of heme synthetase were based on the results of previous studies (21, 22, (27) (28) (29) and on preliminary experiments with rat liver and normal human fibroblast sonicates as the source of enzyme. For assay of activity in fibroblast sonicates, 1.0 ml of a sonicate of 5-10 X 10' cells/ml was added to a 25-ml Erlenmeyer flask containing 0.1 ml Tween-20, 840 umol Tris Cl (pH 7.5), and 100 nmol porphyrin in a final volume of 3.95 ml. The flasks, kept on ice, were capped tightly with rubber diaphragms and flushed with N2 for 3 min. They were then shaken 5 min at 37°C on a Dubnoff shaker after which 0.05 ml 'Fe++ solution was added through the diaphragm to start the reaction, which was allowed to run for 2 h.
Sonicates of liver were incubated similarly except that the flasks contained 750 ,umol Tris Cl and 500 nmol porphyrin, and the duration of incubation was 45 min.
In all experiments, a tissue blank was prepared by boiling a portion of the sonicate for 10 min. Active enzyme preparations were run in duplicate or triplicate concurrently with a single tissue blank. In many experiments a reagent blank (no tissue added) was included as well. Heme synthesis by tissue blanks was equivalent to that of reagent blanks, which for normal fibroblasts was 2-10% that of active enzyme preparations. All results were corrected for nonenzymatic formation of product.
At the end of incubation, hematin was added and the flask contents extracted with 5 and then 2.5 ml ethyl acetate: glacial acetic acid, (4/1 vol: vol). The combined organic layers were washed twice with 5 ml water and once with 2.5 ml 1.5 N HCl, which removed remaining porphyrin. The washed ethyl acetate was counted in a Packard scintillation spectrometer (Packard Instrument Co., Inc., Downers Grove, Ill.; 'Fe counting efficiency 20-30%). After counting, the ethyl acetate was removed by heating to 50-60'C under an N2 stream. The heme residue was dissolved in 0.7 ml pyridine, 3.0 ml water, and 0.30 ml 1 N NaOH were added; and heme concentration of the resulting solution was measured by the pyridine chromogen method of Porra and Jones (22) .
Heme sp act was then determined, and total heme synthesized was calculated as follows: heme synthesized/flask (picomoles) = (heme sp act X heme carrier added X Fe added [picomoles])/5/Fe added (counts per minute). When high levels of heme synthetase activity were present, it was possible to estimate activity by determining the rate of porphyrin disappearance. For this purpose, porphyrin concentration in the HCl wash of ethyl acetate was determined spectrophotometrically (25) .
Chromatography of heme
Column chromatography was performed by the method of Richmond et al. (30) .
Other methods
Porphyrins were quantitated spectrophotometrically or fluorimetrically after extraction by the methods of Schwartz et al. (31) . Proteins were determined by the method of Lowry et al. (32) , with crystalline bovine serum albumin as standard. Student's t test (33) was used to compare data from controls and patients with protoporphyria.
Clinical and biochemical characterization of patients studied
Salient features of the patients with protoporphyria who were studied are summarized in Table I . The diagnosis of protoporphyria was made on the basis of typical history and physical findings of photosensitivity, a positive family history, and demonstration of increased erythrocyte protoporphyrin. Liver biopsy was done in six of the patients and hepatic heme synthetase activity was estimated in five (Table I ). As summarized in Table II , the specimens of the 'Fe++ tracer in incubations in which total product formation was relatively low. As shown in Fig. 2 , under the conditions of the assay, the amount of product formed increased as a function of the amount of liver used and as a function of the time of incubation. The lack of strict linearity has been observed previously (22) ; the reason for this is unknown. In Fig. 3 are shown similar curves for sonicates of fibroblasts from control subjects, in which linear results were obtained for at least 2 h of incubation (Fig. 3A) and for 0-5.5 mg protein (representing 0-13 X 10' cells/flask, Fig. 3B ).
Enzyme activities in fibroblasts. Results of enzyme assays on fibroblast sonicates are summarized in Figs. 4 and 5. Fig. 4 shows that mean activity of ALA synthetase was nearly identical in cells from patients and normals; the mean value (+SD) was 35.6±+13.9 for controls and 38.7±18.5 pmol ALA/mg protein-h for patients.
In contrast, activity of heme synthetase, whether assayed with deuteroporphyrin (Fig. 5A ) or protoporphyrin (Fig. 5B) as substrate, was much lower in sonicates of fibroblasts from patients with protoporphy60r A. protoheme formation in aqueous media (35) . Determinations were run in triplicate, and the coefficient of variation averaged 15%.
Several lines of evidence supported the validity of purifying heme product by ethyl acetate extraction as outlined in Methods. First, two 5-ml water washes were sufficient to remove virtually all water-soluble Fe from the ethyl acetate. Second, as shown in Fig. 1 , when heme residue from washed ethyl acetate was chromatographed, all radioactivity was recovered with the heme, and heme sp act of the eluates was virtually constant and equivalent to that of the starting material. Third, as shown in Fig. 2 , the amount of heme synthesized was similar to the amount of porphyrin utilized when enzymic activity was high.
The equimolar substrate concentrations used in the assays of heme synthetase activity were in the range used previously by other investigators (21, 22, 28, 29, 36) . No excess substrate inhibition with respect to iron or protoporphyrin was observed by Bottomley (21) at concentrations above the maximal concentrations (125 /AM) used here. With 40-100 mg rat liver, an iron concentration ninefold greater produced an activity only 1.4 times that obtained with the 125 *M concentration. This latter concentration was always used in the human liver incubations because it yielded nearly maximal activity with rat liver and because it was felt that higher concentrations would have produced too much dilution In B, incubations were carried out for 45 min, and activity is expressed as a function of the wet wt liver from another male rat. Incubation and assay conditions were as described in Methods. Cell Protein (mg) Enzyme activities in liver biopsies. Results of assays of heme synthetase in human liver biopsies are shown in Fig. 6 . Activities in the five livers from patients with protoporphyria were all low. The lowest value was obtained for patient S. F., who had cirrhosis and heavy pigment deposition on liver biopsy.
Activity of heme synthetase in five of the six control liver biopsies ranged between 273-580 pmol heme/ mg wet wt h. In one control (J. W., Table II ) the activity was 67.3, only slightly above the range of values for protoporphyric subjects. This patient was moderately ill and had had a fever of unknown origin for several weeks before biopsy. He denied drug ingestion which might have accounted for diminished heme synthetase activity, e.g., chloramphenicol (37) , and no explanation for the finding is apparent. The mean activity (+SD) for all controls was 352±171 while for patients with protoporphyria the value was 44.2±20.5 pmol heme/mg wet wt * h, a highly significant difference. With protoporphyrin as substrate the mean heme synthetase activity in livers of patients with protoporphyria was 13% of control and in fibroblasts was 14%, a closely similar value.
DISCUSSION
These studies demonstrate a striking decrease in activity of heme synthetase in sonicates of cultured skin fibroblasts and liver from patients with protoporphyria. In interpreting the significance of this finding, a number of questions may be considered.
First, the question may be raised as to whether the low activities could be due to enzyme inhibition by excess substrate, either iron or porphyrin. In preliminary studies, Fe`+ at 10 times the concentration used in our assay did not diminish activity, suggesting that mammalian hepatic heme synthetase, like erythroid heme synthetase (21), is not inhibited by excess Fe". In any event, iron as estimated by histochemical stain was not increased in the livers of the patients with protoporphy- lated to excess substrate inhibition (24) or abnormal lability of mRNA for heme synthetase (38) ; however, neither of these seems likely to explain our findings. Furthermore, the low activities observed in patient fibroblasts, which had been cultured in vitro for several generations, rule out the possibility of inhibitor(s) which might have originated from another tissue of the patient.
Since heme synthesis in normal cells appears to be controlled primarily by the level of ALA synthetase activity, which is subject to end-product inhibition and repression (6), the question arises why ALA synthetase activity, as measured here, was not increased in the fibroblasts in which heme synthetase activity was markedly decreased. In considering this finding it should be borne in mind that the assay used for ALA synthetase measures the overall conversion of a-ketoglutarate to ALA in the presence of pyridoxal phosphate and glycine in high concentration. Thus, it is theoretically possible that the generation of succinyl-CoA from a-ketoglutarate was rate limiting, not the activity of ALA synthetase itself. Previously, however, whole liver homogenate, similarly incubated, has been found to generate succinyl-CoA at apparently optimal rates, even for very high levels of ALA synthetase (39) . In frozenthawed preparations of viral-transformed cells cultured in vitro, induction of ALA synthetase has been demonstrated by using our radioassay (26) , and this induced activity remains intact after several weeks of frozen storage.' Furthermore, activities observed in the present studies, in preparations of fibroblasts stored frozen, were, if anything, higher than those we previously observed in preparations from fibroblasts assayed immediately after harvesting (19) . Thus, cell freezing and storage do not decrease activity of ALA synthetase as determined by this assay, and apparent induction can be demonstrated in frozen-thawed preparations of cell lines grown in vitro. These considerations suggest that our assay would have detected an increase in ALA synthetase had it been present.
From the lack of porphyrin accumulation by the intact cells of patients or controls, it may be concluded that activity of the steps in the heme pathway between uroporphyrinogen and heme were not rate limiting under the growth conditions used. Rather, it seems likely that generation of ALA was rate limiting in both types of intact cells, as is the case for normal liver (6), a suggestion supported by the observation that skin fibroblasts grown in the presence of exogenous ALA accumulate protoporphyrin.' The lack of apparent induction of ALA synthetase in fibroblasts from porphyric sub-'Ebert, P. S. Unpublished observations. 'Bloomer, J. R. Unpublished observations. jects, despite a partial "block" in heme synthesis distal to ALA may simply be due to the fact that the demand for heme synthesis by these cells is insufficient to derepress ALA synthetase. Several other possible explanations have been discussed previously (19) .
Protoporphyrin production and excretion is increased in another heritable disorder of porphyrin metabolism, variegate porphyria (6), as well as in protoporphyria. The metabolic basis for the apparent increase in protoporphyrin (and other porphyrin) production in variegate porphyria is imperfectly understood; a reasonable postulate would be that there is an inborn deficiency of heme synthetase activity. Were such a decrease to be found, it would complicate further interpretation of the observations reported here. However, in the single study thus far published (40) , heme synthetase activity was normal in muscle tissue from variegate subjects. This finding, if confirmed, indicates that in this disease protoporphyrin accumulates for reasons other than that demonstrated here for protoporphyria, perhaps due to deficient activity of protoporphyrinogen oxidase with increased biliary secretion of protoporphyrinogen which is oxidized to protoporphyrin in the gut or during fecal analysis.
The tissue sources responsible for protoporphyrin overproduction in protoporphyria remain uncertain. Experiments of similar design in two patients (5, 23) led to divergent interpretations concerning the relative importance of liver and erythroid tissue as possible sources. While our studies did not address this problem directly, the deficiency of hepatic heme synthetase activity in our patients is compatible with the liver as a source under certain circumstances. In none of the patient livers was heme synthetase activity less than the rate at which normal mammalian liver appears to synthesize ALA or require heme (41) . However, the one patient with hepatic pigment deposition (patient S. F.), had heme synthetase activity of only 10.1 pmol heme/mg wet wt -h. If this figure is close to the maximal rate at which hepatic heme can be synthesized by this patient, only a modest induction (three-times normal) of liver ALA synthetase would be required to exceed the capacity of heme synthetase to metabolize endogenously produced protoporphyrin. Since hepatic ALA synthetase can be induced to very high levels and since the rate of total hepatic aminoketone synthesis has been found increased above three-times normal in a few protoporphyria patients previously (42) , it seems possible that the liver overproduces protoporphyrin, at least episodically, in some patients with this disorder.
In this regard it should also be stressed that an increase in ALA synthetase activity, leading to an increased pool of protoporphyrin, might need to be only a temporary or episodic phenomenon, until 
